Since then, another four immune checkpoint inhibitors targeting PD-1 or PD-L1 for locally advanced and metastatic bladder cancer, including Nivolumab, Pembrolizumab, Avelumab, and Durvalumab have been approved by FDA for bladder cancer (8–10). The gene discussed is CD274; the disease is urinary bladder carcinoma.